manufacture refraction instruments, ophthalmic diagnostic instruments, visual acuity chart, ophthalmic unit, electric table，One stop medical instrument
Currency:
USD
USD EUR GBP JPY AED AUD BRL CAD CHF DKK HKD IDR INR KRW MOP MYR NOK NZD PHP RUB SAR SEK THB TRY TWD SGD ZAR
Language:
English
English Deutsch Français Русский にほんご 한국어 Español Português Italiano العربية Nederlands Ελληνικά
Sign In or Join Free
English
English
Deutsch
Français
Русский
にほんご
한국어
Español
Português
Italiano
العربية
Nederlands
Ελληνικά
USD
USD
EUR
GBP
JPY
AED
AUD
BRL
CAD
CHF
DKK
HKD
IDR
INR
KRW
MOP
MYR
NOK
NZD
PHP
RUB
SAR
SEK
THB
TRY
TWD
SGD
ZAR
Search History
You May Also Like
Clinic PD measurement device, Optical shop pupillometer, CE certified PD meter Optical shop lens power meter ,Hospital lens testing equipment, CE certified lensometer supplier Ophthalmoscope, Direct Ophthalmoscope, Indirect Ophthalmoscope Auto Refractometer，Digital Refractometer，Ophthalmic Equipment，Vision Testing Device，Eye Refractometer，Optometry Instrument Hospital color blindness test, Optical shop color vision tool, CE certified color test book, Professional ophthalmic test book, Portable color blind test Optometry Lift Table，Adjustable Optometry Table，Electric Lift Table， Portable auto refractometer, Clinic vision testing equipment, Eye care center refractometer Hospital ophthalmic patient chair, Comfortable optometry examination chair, Custom optometry patient chair OEM Anti-Slip Glasses Pads, Silicone Lens Stickers, Eyewear Anti-Slip Pads, Glasses Nose Pads, Anti-Slip Lens Patches, Silicone Glasses Stickers, Rightway Optical Anti-Slip Pads, Glasses Grip Pads, Eyewear Comfort Pads, Glasses Non-Slip Stickers
News
AbbVie and REGENXBIO Announce Eye Care Collaboration
News
AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration

November 21, 2021
AbbVie photo

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) recently announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

WhatsApp